MELD-Na > 16 is associated with high peri-procedural and short-term mortality in patients with ruptured hepatocellular carcinoma treated with emergent transarterial embolization

2021 ◽  
Author(s):  
Michael C. Jundt ◽  
Robert L. Owen ◽  
Scott M. Thompson ◽  
Chad J. Fleming ◽  
Andrew H. Stockland ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Embolization ◽  
Short Term ◽  
Short Term Mortality ◽  
Ruptured Hepatocellular Carcinoma

Survival after transarterial embolization for spontaneous ruptured hepatocellular carcinoma

2009 ◽  
Vol 16 (4) ◽  
pp. 508-512 ◽  
Author(s):  
Wing-Hong Li ◽  
Edmond Cheung-Yan Cheuk ◽  
Philip Chong-Hei Kowk ◽  
Moon-Tong Cheung
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Embolization ◽  
Ruptured Hepatocellular Carcinoma

scholarly journals Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma

2017 ◽  
Vol 11 (1) ◽  
pp. 155-161
Author(s):  
Severin Gloor ◽  
Kai Oliver Jensen ◽  
Stefan Breitenstein ◽  
Christoph A. Binkert ◽  
Eliane Angst ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Rare Case ◽  
Transarterial Embolization ◽  
Interdisciplinary Approach ◽  
Emergency Situation ◽  
Bridging Therapy ◽  
Perioperative Morbidity ◽  
Ruptured Hepatocellular Carcinoma ◽  
Viral Infection Status ◽  
Diagnostics And Therapy

Spontaneous ruptures of hepatocellular carcinoma (HCC) are rare. Nevertheless they may lead to difficult decisions in the emergency situation. The acute therapies include conservative treatment, transarterial embolization and surgery. Curative treatment of HCC can be achieved by liver resection solely. The decision-making depends on prognostic patient’s factors, such as hepatic viral infection status, Child-Pugh grade, liver cirrhosis and number of tumors. In this case transarterial embolization was preferable as a bridging therapy prior to further diagnostics and therapy, to lower the perioperative morbidity and mortality. The therapy of these cases needs an interdisciplinary approach to choose the best possible procedure in each case.

FRI-456-MELD score is the only predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by emergent transarterial embolization

2019 ◽  
Vol 70 (1) ◽  
pp. e596
Author(s):  
Ya-Ting Cheng ◽  
Wei Teng ◽  
Rachel Wen-Juei Jeng ◽  
Yi-Chung Hsieh ◽  
Kar-Wai Lui ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Embolization ◽  
Meld Score ◽  
Ruptured Hepatocellular Carcinoma

scholarly journals The feasibility of transcatheter arterial chemoembolization following radiation therapy for hepatocellular carcinoma

2021 ◽  
Vol 10 (7) ◽  
pp. 205846012110349
Author(s):  
Mostafa Hamada ◽  
Eisuke Ueshima ◽  
Takeaki Ishihara ◽  
Yutaka Koide ◽  
Takuya Okada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Function ◽  
Transcatheter Arterial Chemoembolization ◽  
Survival Duration ◽  
High Dose ◽  
Short Term ◽  
Liver Function Impairment ◽  
Function Impairment ◽  
Short Term Mortality ◽  
Arterial Chemoembolization

Background Technological developments have led to an increased usage of external-body radiotherapy (RT) for the treatment of hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) may be required later in patients treated with RT because of the high recurrence rate and multinodular presentation of HCC. However, despite the risk of liver function impairment, the cumulative liver damage correlated with TACE following a hepatic RT has not been adequately assessed. Purpose To evaluate the feasibility of TACE following RT for HCC. Materials and methods Sixty-seven patients with HCC who underwent TACE after RT were retrospectively evaluated between 2012 and 2018. We assessed increases in Child–Turcotte–Pugh (CTP) by ≥2 points at 1 month, the incidence of major complications, survival duration, and short-term mortality within 6 months after TACE. Furthermore, we evaluated the predictive factors for liver function impairment and short-term mortality. Results Eight patients experienced a CTP increase ≥2 points at 1 month. There were no cases of liver abscesses or bilomas. Nine patients died within 6 months following TACE. The mean liver dose (MLD) was a significant predictor of liver function impairment at 1 month ( p = 0.042). Low liver functional reserve, distant metastasis ( p = 0.037), MLD ( p = 0.046), TACE type ( p = 0.025), and TACE within 3 months following RT ( p = 0.007) were significant predictors of short-term mortality. Conclusions Despite the feasibility of TACE following RT, clinicians should pay attention to impaired pretreatment liver function, following high dose RT, and the short duration between RT and TACE.

Sign in / Sign up

Export Citation Format

Share Document